Side-by-side comparison of AI visibility scores, market position, and capabilities
Major US chocolate company with $11B revenue; Reese's and Hershey's chocolate plus Kit Kat under license managing cocoa inflation from 2024 historic price spikes competing with Mars.
The Hershey Company is one of the world's largest chocolate manufacturers, producing iconic confectionery brands including Hershey's chocolate bars, Reese's peanut butter cups, Kit Kat (in the US, under license from Nestlé), Jolly Rancher, Almond Joy, Mounds, and Kisses. Listed on NYSE (NYSE: HSY) and headquartered in Hershey, Pennsylvania (a company town literally built around the chocolate factory), Hershey generates approximately $11 billion in annual revenue and commands significant market share in the US confectionery market.\n\nHershey's product portfolio spans milk chocolate, dark chocolate, white chocolate, peanut butter chocolate combinations (Reese's is consistently one of the top-selling confectionery brands in the US), hard candy (Jolly Rancher), gum, and snack bars. The Reese's brand is Hershey's largest and most strategically important, generating billions in annual sales with consistent category leadership in the peanut butter confectionery segment. Hershey also owns salty snacks (SkinnyPop popcorn, Dot's Pretzels) as part of its snacking expansion.\n\nIn 2025, Hershey faces significant cocoa cost inflation — cocoa prices reached historic highs in 2024 as West African crop failures created supply shortages, forcing Hershey and other chocolate manufacturers to take significant price increases that have pressured volume. The company competes with Mars, Inc. (M&Ms, Snickers, Twix), Mondelez (Cadbury, Toblerone), and Lindt for confectionery market share. Hershey's 2025 strategy focuses on managing cocoa cost volatility through pricing and hedging, growing its salty snacks segment as a less cocoa-dependent growth lever, and maintaining brand equity of core chocolate brands despite price increases.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.